These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 23358401

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper.
    Traino AC, Di Martino F, Grosso M, Monzani F, Dardano A, Caraccio N, Mariani G, Lazzeri M.
    Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355
    [Abstract] [Full Text] [Related]

  • 5. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
    Traino AC, Di Martino F, Lazzeri M.
    Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D, Epstein M, Lan L, Tan P, Booker J.
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
    Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, Volterrani D, Chiacchio S, AlSharif A, Borsò E, Raschillà R, Di Martino F, Mariani G.
    Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
    [Abstract] [Full Text] [Related]

  • 10. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
    Canzi C, Zito F, Voltini F, Reschini E, Gerundini P.
    Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A practical method for the estimation of therapeutic activity in the treatment of Graves' hyperthyroidism.
    Panareo S, Rossi R, Fabbri S, De Paola G, Candini GC, Feggi L, Degli Uberti E.
    Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):576-85. PubMed ID: 21068711
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M, Moka D, Reinholz U, Schmidt M, Schomäcker K, Schicha H, Wellner U.
    Nuklearmedizin; 2007 Oct; 46(3):77-84. PubMed ID: 17549318
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves' disease.
    Traino AC, Xhafa B.
    Med Phys; 2009 Apr; 36(4):1212-8. PubMed ID: 19472628
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ, de Klerk JM.
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.